Stryker vs Vertex (SYK vs VRTX)

Stryker (SYK) vs Vertex (VRTX) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

Stryker (SYK) and Vertex (VRTX) compete in healthcare and pharma. Here are Stryker and Vertex side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Stryker or Vertex.

Stryker vs Vertex: the figures

Stryker and Vertex figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Stryker or Vertex figure is not available, and we never estimate it.

3 key differences between Stryker and Vertex

1. Profitability: for every 100 of sales, Vertex keeps 30.7 as net profit and Stryker keeps 13.8.
2. Volatility: Stryker stock moves more (beta 0.77) than Vertex (beta 0.28); the higher the beta, the more it amplifies market swings.
3. Debt: Stryker owes 1.6x its annual operating profit (EBITDA), while Vertex owes 0.0x its EBITDA.

Stryker or Vertex: which fits your profile

• If you want growth: Vertex is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
• If you want income (dividends): Stryker pays the higher dividend relative to its price.
• If you prefer caution: Vertex has less debt relative to its profit, which usually gives more room in a bad year.
• If price is what matters most to you: Stryker trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.

Neither Stryker nor Vertex wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How Stryker and Vertex make money

Stryker (SYK)

Stryker sells medical equipment to hospitals through two segments. MedSurg and Neurotechnology covers surgical instruments, emergency equipment, hospital beds and neurovascular devices, while Orthopaedics includes hip and knee implants and the Mako surgical robot. The United States is its largest market, followed by Europe and Asia. Full Stryker analysis.

Vertex (VRTX)

Vertex Pharmaceuticals earns most of its revenue from cystic fibrosis drugs such as Trikafta, sold as Kaftrio in Europe, and Alyftrek. It has broadened its lineup with Casgevy, a gene-editing therapy for sickle cell disease, and Journavx, a non-opioid pain medicine. The United States and Europe are its biggest markets. Full Vertex analysis.

Frequently asked questions: Stryker vs Vertex

Is Stryker or Vertex the better stock?

Choosing between Stryker and Vertex depends on what you are looking for. Vertex is growing faster right now, and Stryker trades on the lower P/E. Fintols does not tell you whether to buy Stryker or Vertex: it shows you the differences so you can decide.

Which pays a higher dividend, Stryker or Vertex?

As of November 4, 2026, Stryker yields 1.13% and Vertex pays none. Also check how much of their profit Stryker and Vertex pay out: if it is more than they earn, it cannot last.

Which is more expensive, Stryker or Vertex?

On P/E, Vertex (36.8x) is more expensive than Stryker (36.2x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both Stryker and Vertex?

Yes. Many people spread their money across several companies, such as Stryker and Vertex, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Stryker or Vertex.

More comparisons with Stryker or Vertex

• Boston Scientific vs Stryker
• Novo Nordisk vs Stryker
• Boston Scientific vs Vertex
• Novo Nordisk vs Vertex

More companies like Stryker and Vertex: healthcare and pharma stocks. Educational content about Stryker and Vertex, not investment advice.